Altimmune (NASDAQ: ALT) is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID?), anthrax (NasoShield?) and influenza (NasoVAX?); an intranasal immune modulating treatment for COVID-19 (T-COVID?); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell?).